Aug 03, 2023 4:05 pm EDT CymaBay Therapeutics to Report Second Quarter of 2023 Financial Results on Thursday, August 10, 2023
Jun 21, 2023 3:00 am EDT CymaBay Therapeutics Presents Data Showing Seladelpar Treatment in Primary Biliary Cholangitis (PBC) Correlates with Alleviation of Self-Reported Pruritus and Reduction in Serum IL-31 Levels
Jun 07, 2023 2:00 am EDT CymaBay Therapeutics to Present New Data Highlighting Seladelpar's Unique Activity in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2023
May 15, 2023 4:04 pm EDT CymaBay Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 10, 2023 8:00 am EDT CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023
Apr 21, 2023 8:00 am EDT CymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC)
Apr 17, 2023 8:00 am EDT CymaBay Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
Mar 16, 2023 4:04 pm EDT CymaBay Reports Fourth Quarter and Year Ended December 31, 2022 Financial Results and Provides Corporate Update
Mar 09, 2023 4:05 pm EST CymaBay Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023